Table 1.
Baseline characteristics of healthy controls and IPF patients
| Pilot study | Validation study | |||
|---|---|---|---|---|
| Healthy | IPF | Healthy | IPF | |
| Subjects (male %) | 10 (90) | 10 (90) | 10 (60) | 11 (82) |
| Age (years) | 68.7 ± 7.9 | 67.8 ± 8.6 | 32.4 ± 15.3 | 66.1 ± 8.6 |
| BMI kg/m2 | 28.9 ± 5.1 | 26.9 ± 3.6 | 22.6 ± 2.7 | 26.3 ± 4.3 |
| BMI ≥ 25 kg/m2 | 7 | 5 | 2 | 6 |
| Diabetes mellitus type 2 (n) | 1 | 2 | 0 | 3 |
| Hypertension | 5 | 5 | 0 | 3 |
| Lung function | ||||
| FVC, L | 4.1 ± 0.4 | 2.4 ± 0.5 | 4.5 ± 1.0 | 2.4 ± 0.6 |
| FVC (% predicted) | 114.6 ± 8.5 | 65.1 ± 11.3 | 94.0 ± 10.3 | 63.1 ± 14.3 |
| DLCO (% predicted) | 129.6 ± 31.1 | 43 ± 15.0 | 87.8 ± 11.3 | 44.6 ± 14.6 |
| GAP Stage (I-III) | – | I - II | – | I- II |
| Smoking status | ||||
| Current Smokers n (median pack years ± SD) | 0 | 0 | 5 (8.2 ± 14.5) | 0 |
| Former Smokers n (median pack years ± SD) | 8 (5.5 ± 5.7) | 8 (25.4 ± 15.2) | 0 | 8 (13.9 ± 13.3) |
| Antifibrotic therapy | ||||
| Pirfenidone n (%) | – | 6 (60) | – | 6 (54.5) |
| Nintedanib n (%) | – | 3 (30) | – | 4 (36.4) |
| No antifibrotics n (%) | – | 1 (10) | – | 1 (9.1) |
FVC Forced vital capacity, DLCO Diffusing capacity of the lung for carbon monoxide, BMI Body Mass Index